Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity

Aug 27 2007

• By Jamie Hammon

Related Content

Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa

Aug 27 2007

FDA Weighs Next Move After Appellate Court Rebuffs Patent Delisting Policy

Nov 20 2006

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window